€1m project marks regulatory affairs provider’s entry into the pharmaceutical development market
ELC Group, one of the fastest growing providers of regulatory affairs services, has signed up for the early stage development of a novel vaccine targeting the prevention of influenza.
The project signals ELC Group’s entry into the pharmaceutical development market. The vaccine development will be overseen by a specialist R&D team at ELC Group, including regulatory experts who have worked on and regulated a number of key worldwide paediatric vaccines.
The experienced team includes a number of current advisers to the World Health Organisation. ELC Group is working with preclinical partners to do toxicity and immunogenicity testing, and is harnessing innovative new techniques to create the novel vaccine. ELC Group will also be responsible for setting up the regulatory pathway to ensure a smooth transition to market and approval from international regulators.
‘We are very excited to be moving into the pharmaceutical development market with this key launch project, targeting an important therapeutic area,' ELC Group CEO Marco Rubinstein said. 'With the ability to take this product through our concept to commercialisation model by our unrivalled team of world-class experts, we are confident of a successful project delivery.’